Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03014063 · ClinicalTrials.gov registry record

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

A clinical trial of Septic Shock, sponsored by The Cleveland Clinic.

Completed
Registry status
18
Enrollment target
1
Study location

NCT03014063 is a study of Septic Shock that has completed, run by The Cleveland Clinic. The registered enrollment target is 18 participants, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03014063, a study of Septic Shock, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
18 participants
Enrollment target
1
Study location

Study Summary

This is a prospective observational cohort trial evaluating a single plasma vasopressin concentration in patients receiving exogenous, adjunctive vasopressin for septic shock. The trial is designed to determine whether plasma vasopressin concentration influences the likelihood of hemodynamic response to exogenous vasopressin therapy.

Conditions Studied

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2016-11
Est. Completion 2017-06

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT03014063

The ClinicalTrials.gov registry entry for NCT03014063 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,058-participant average among 24 other Septic Shock trials with a reported enrollment target (100% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Septic Shock appearing as the primary indexed condition, and to 0 interventions.

NCT03014063 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03014063 about?

NCT03014063 is a clinical study titled "Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock". This is a prospective observational cohort trial evaluating a single plasma vasopressin concentration in patients receiving exogenous, adjunctive vasopressin for septic shock. The trial is designed to determine whether plasma vasopressin concentration influences the likelihood of hemodynamic respons...

What is the current status of trial NCT03014063?

This trial is currently completed. The enrollment target is 18 participants. The study started on 2016-11. Estimated completion is 2017-06.

What conditions does trial NCT03014063 study?

This clinical trial studies the following conditions: Septic Shock.

Who is sponsoring clinical trial NCT03014063?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03014063 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Septic Shock

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.